Based on the Biocon Limited stock forecast from 2 analysts, the average analyst target price for Biocon Limited is INR 383.00 over the next 12 months. Biocon Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biocon Limited is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Biocon Limited’s stock price was INR 360.95. Biocon Limited’s stock price has changed by -2.25% over the past week, -1.88% over the past month and +31.54% over the last year.
No recent analyst target price found for Biocon Limited
No recent average analyst rating found for Biocon Limited
Company Overview Biocon Limited
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Read Less
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. ...Read More
Frequently Asked Questions About Biocon Limited (BIOCON:NSE) Stock
Based on ratings from 2 analysts Biocon Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
BIOCON:NSE stock's dividend yield is 0.14%.
Our analysis grades BIOCON:NSE stock's dividend yield at F. This means that BIOCON:NSE stock's dividend yield is above 33% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this BIOCON:NSE may be a poor dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for BIOCON:NSE is INR 383.00 over the next 12 months. The maximum analyst target price is INR 390 while the minimum anlayst target price is INR 376.
BIOCON:NSE stock's Price/Earning ratio is 29.33.
Our analysis grades BIOCON:NSE stock's Price / Earning ratio at D. This means that BIOCON:NSE stock's Price/Earning ratio is above 36% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this BIOCON:NSE may be fairly valued for its sector
The last closing price of BIOCON:NSE's stock was INR 360.95.
The most recent market capitalization for BIOCON:NSE is INR 422.23B.
Based on targets from 2 analysts, the average taret price for BIOCON:NSE is projected at INR 383.00 over the next 12 months.
This means that BIOCON:NSE's stock price may go up by +6.11% over the next 12 months.
We can't find any ETFs which contains Biocon Limited's stock.
As per our most recent records Biocon Limited has 16,315 Employees.
Biocon Limited's registered address is 20th KM Hosur Road, Bengaluru, India, 560100.
You can get more information about it from Biocon Limited's website at https://www.biocon.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Biocon Limited (BIOCON:NSE) Stock
Based on ratings from 2 analysts Biocon Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
BIOCON:NSE stock's dividend yield is 0.14%.
Our analysis grades BIOCON:NSE stock's dividend yield at F. This means that BIOCON:NSE stock's dividend yield is above 33% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this BIOCON:NSE may be a poor dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for BIOCON:NSE is INR 383.00 over the next 12 months. The maximum analyst target price is INR 390 while the minimum anlayst target price is INR 376.
BIOCON:NSE stock's Price/Earning ratio is 29.33.
Our analysis grades BIOCON:NSE stock's Price / Earning ratio at D. This means that BIOCON:NSE stock's Price/Earning ratio is above 36% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this BIOCON:NSE may be fairly valued for its sector
The last closing price of BIOCON:NSE's stock was INR 360.95.
The most recent market capitalization for BIOCON:NSE is INR 422.23B.
Based on targets from 2 analysts, the average taret price for BIOCON:NSE is projected at INR 383.00 over the next 12 months.
This means that BIOCON:NSE's stock price may go up by +6.11% over the next 12 months.
We can't find any ETFs which contains Biocon Limited's stock.
As per our most recent records Biocon Limited has 16,315 Employees.
Biocon Limited's registered address is 20th KM Hosur Road, Bengaluru, India, 560100.
You can get more information about it from Biocon Limited's website at https://www.biocon.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIOCON:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
